Questions for Successfully Screened Applicants

X/Twitter

This field is for validation purposes and should be left unchanged.

First name(Required)

Last name(Required)

Email address(Required)

Contact number(Required)

Organisation(Required)

Job title(Required)

Which indication do you intend to target (tick all that apply)

Bronchiectasis

Cystic Fibrosis

What therapeutic mechanism(s) would your drug have (tick all that apply)

Anti-infective

Anti-inflammatory

Airway clearance / Mucus thinning

Protease inhibiting

Regenerative therapy

Other (please specify)

Please identify the drug(s) you intend working with, and – if known – the drug patent status. Please also indicate what engagement you have had with the owner (or generics manufacturer) to date.(Required)

What is the current scientific stage of evidence supporting potential efficacy of your proposed drug in Bronchiectasis or Cystic Fibrosis(Required)

Idea based on scientific rationale only

Supported with relevant in vitro cell-based evidence

Supported by relevant translational in vivo evidence

Some supportive clinical data

Please briefly describe the scientific rationale supporting your repurposing idea(Required)

If LifeArc were to support you in taking your proposed repurposing idea to the next stage of validation, what would you be able to provide, and where would you need support from us and our networks? For example, indicate what is available in terms of disease biology expertise, cell lines, pathogen strains, preclinical models, clinical development expertise.(Required)

Please provide anything known about your proposed drug in terms of:

Drug status: has the drug been tested in any related respiratory indication (e.g. Primary Ciliary Dyskinesia).(Required)

Safety: what is known about the drug’s side effects from human use? Are there any known drug-drug interactions? Would any of these be problematic in a CF/BE setting?(Required)

Lung exposure: if lung exposure would be required for the drug’s efficacy in CF/BE, is there evidence of it reaching therapeutically relevant concentrations in the lung?(Required)

Reformulation requirements: would reformulation be required for appropriate use in Bronchiectasis or Cystic Fibrosis patients?(Required)

Use in patients: how would your drug fit within the current care pathway, and has acceptability of the new drug to patients been considered?(Required)

Questions for eligible applicants

Please provide anything known about your proposed drug in terms of: